

BIBLIOGRAFIA

1 dal sito: http://www.salute.gov.it/portale/salute/p1_5.jsp?id=166&area=Malattie_infettive

2 Minardi D, d' Anzeo G, Cantoro D, Conti A, Muzzonigro G.
Urinary tract infections in women: etiology and treatment options.
International Journal of General Medicine. 2011; 4: 333-343

3 Horan TC, Andrus M, Dudeck MA. CDC/NHSN
surveillance definition of health care-associated infection and criteria for specific types of
infections in the acute care setting.
Am J Infect Control 2008;36:309–32.

4 Katouli M.
Population structure of gut *Escherichia coli* and its role in development of extra-intestinal
infections.
Iranian Journal of Microbiology. 2010;2(2):59-72.

05 Hooton TM.
Recurrent urinary tract infection in women.
Int J Antimicrob Agents 2001;17:259-68.

6 Raccomandazioni in tema di diagnosi, trattamento e profilassi delle infezioni delle vie urinarie
Versione 1, 2015, Battaglia et al. (Comitato Linee Guida della Società Italiana di Urologia)

7 dal sito: <https://www.nih.gov/news-events/news-releases/federal-prize-competition-seeks-innovative-ideas-combat-antimicrobial-resistance>

8 dal sito: http://ec.europa.eu/dgs/health_food-safety/amr/index_en.htm

9 Berepoot and S. Geerlings.
Non-antibiotic prophylaxis for urinary tract infection.
Pathogens 2016, 5, 36;

10 Wagenlehner FM, Vahlensieck W, Bauer HW, Weidner W, Piechota HJ, Naber KG.
Prevention of recurrent urinary tract infections.
Minerva Urol. Nefrol. 2013; 65: 9–20.

11. Fowler JE Jr, Pulaski ET.
Excretory urography, cystography, and cystoscopy in the evaluation of women with urinary-
tract infection: a prospective study.
N Engl J Med 1981 Feb;304(8):462-5

- 12 108 Albert, X.; Huertas, I.; Pereiro, I.I.; Sanfelix, J.; Gosalbes, V.; Perrota, C.
Antibiotics for preventing recurrent urinary tract infection in non-pregnant women.
Cochrane Database Syst. Rev. 2004, CD001209. [CrossRef]
- 13 .Vosti KL.
Recurrent urinary tract infections. Prevention by prophylactic antibiotics after sexual intercourse.
JAMA 1975;231:934-940.
- 14 Badreldin H. Ali¹ , Naser Al Wabel¹ and Gerald Blunden
Phytochemical, Pharmacological and Toxicological Aspects of Hibiscus sabdariffa L.: A Review
PHYTOTHERAPY RESEARCH Phytother. Res. 19, 369–375 (2005)
- 15 500AMcKay, Diane L., et al.
"Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults.
" *The Journal of nutrition* 140.2 (2010): 298-303.
- 16 Ali, B.H., Wabel, N.A., Blunden, G., 2005.
Pharmacological and toxicological aspects of Hibiscus sabdariffa L.
Phytotherapy Research 19, 369–375
- 17 500 Issam Alshami, Ahmed Eid Alharbi
Antimicrobial activity of Hibiscus sabdariffa extract against uropathogenic strains isolated from recurrent urinary tract infections
Asian Pac J Trop Dis 2014; 4(4): 317-322
- 18 31 Berepoot and S. Geerlings.
Non-antibiotic prophylaxis for urinary tract infection.
Pathogens 2016, 5, 36
- 19 300 300 Foxman B.
Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.
Dis Mon. 2003;49(2):53-70.
- 20 301 Foo LY, Lu Y, Howell AB, Vorsa N:
A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. *J Nat Prod* 2000, 63:1225-1228.
- 21 302 Jepson RG, Craig JC.
Cranberries for preventing urinary tract infections.
Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001321.

22 303 Chih-Hung Wang, MD; Cheng-Chung Fang, MD; Nai-Chuan Chen, MD; Sot Shih-Hung Liu, MD; Ping-Hsun Yu, MD;

Tao-Yu Wu, MD; Wei-Ting Chen, MD; Chien-Chang Lee, MD, MSc; Shyr-Chyr Chen, MD, MBA
Cranberry-Containing Products for Prevention of Urinary Tract Infections in Susceptible Populations

ARCH INTERN MED/VOL 172 (NO. 13), JULY 9, 2012 988.

23 304 Stothers, L. (2002).

A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract'.

The Canadian Journal of Urology 9 (3);

24 Marcucci, Maria Cristina.

"Propoli: composizione chimica, le proprietà biologiche e attività terapeutica".

Apidologie 26.2 (1995): 83-99.

25 Drago, L., et al.

"In vitro antimicrobial activity of propolis dry extract."

Journal of chemotherapy 12.5 (2000): 390-395

26 307 Lavigne J-P, Vitrac X, Bernard L, Bruyère F, Sotto A.

Propolis can potentialise the anti-adhesion activity of proanthocyanidins on uropathogenic *Escherichia coli* in the prevention of recurrent urinary tract infections.

BMC Research Notes. 2011;4:522.

27 32A Foo LY, Lu Y, Howell AB, Vorsa N:

A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated *Escherichia coli* J

Nat Prod. 2000 63: 1225-1228.

28 32 305 Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, Tenke P, Sotto A, Lavigne JP:

Dosage effect on uropathogenic *Escherichia coli* anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. *BMC Infect Dis* 2010, 10:94.

29 306 Lavigne JP, Bourg G, Combescure C, Botto H, Sotto A:

In-vitro and in vivo evidence of dose-dependent decrease of uropathogenic *Escherichia coli* virulence after consumption of commercial *Vaccinium macrocarpon* (cranberry) capsules.

Clin Microbiol Infect 2008, 14:350-355.

30 789: dal sito: <http://www.bnatural.it>

